Vertex Pharmaceuticals was a shining star amongst the already bright biotech industry. In the nearly decade-long stretch between 2012 and 2020, it quadrupled the growth in the S&P 500. But as of late Vertex is slipping, down 25% since October since news broke about the halt of a new drug treatment. A drug intended to treat lung and liver disorder AATD was a bust, which caused the company that made its mark treating cystic fibrosis to slip. However, the fundamentals that allowed Vertex to climb in the 2010s are still present. Vertex continues to innovate in cystic fibrosis, with a new drug entering phase three of research, and Vertex has another play with AATD. It plans to enter the new drug into play for phase two of treatment in Q2. The company has considered acquisitions outside the company, but Vertex has assured investors of a robust development pipeline.
FINSUM + Magnifi: Investors need constant innovation for a company to stay on a solid growth trajectory, and Vertex’s slip-up with AATD halted their progress. A new development could put them right back on track as one of healthcare’s darlings.
Magnifi is changing the way we shop for investments, with the world’s first semantic search engine for finance that helps users discover, compare and buy investment products such as ETFs, mutual funds and stocks. As of March 2021, 250,000+ users with $475+ Billion in Assets Under Influence, has used Magnifi over 1,200,000 times. Try it for yourself today.
This blog is sponsored by Magnifi. The information and data are as of the publish date unless otherwise noted and subject to change. This material is provided for informational purposes only and should not be construed as individualized investment advice or an offer or solicitation to buy or sell securities tailored to your needs. This information covers investment and market activity, industry or sector trends, or other broad-based economic or market conditions and should not be construed as investment research or advice. Investors are urged to consult with their financial advisors before buying or selling any securities. Although certain information has been obtained from sources believed to be reliable, we do not guarantee its accuracy, completeness or fairness. Past performance is no guarantee of future results. This content may not be reproduced or distributed to any person in whole or in part without the prior written consent of Magnifi. [As a technology company, Magnifi provides access to tools and will be compensated for providing such access. Magnifi does not provide brokerage or custody services.]